XCSport体育
About Henlius
Company Profile
XCSport体育:Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
XCSport体育:Products in R&D
XCSport体育:Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
XCSport体育:Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
XCSport体育:Financial Reports
Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
XCSport体育:Multi-media
XCSport体育:Media Reports
Media Enquiry
Careers
Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
XCSport体育:About Henlius
XCSport体育:Company Profile
Corporate Culture
Honor
Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
XCSport体育:Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
XCSport体育:Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
XCSport体育:Media Enquiry
Careers
XCSport体育:Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
XCSport体育:Contact Information
XCSport体育:Customer Message
Privacy
XCSport体育:Legal Statement
XCSport体育:Compliance
搜索
Be the most trusted biotech company
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
XCSport体育:Popular Science
Highlights
Download
XCSport体育:Media Reports
Media Enquiry
2026-02-20
Global Second PD-L1 ADC: Henlius’ HLX43, a Novel PD-L1 ADC, Advances to Phase 2 Clinical Trials with First Patient Dosed
2022-11-18
Making biologic medicines more accessible
Global biopharmaceutical company Henlius aims to greatly improve patient well-being with affordable and innovative biologic medicines
2021-02-14
Shanghai Henlius CEO Wants To Capitalize On First-Mover Status
Generics Bulletin
2020-05-09
An original force in biosimilars
Nature Research
2019-06-27
Growing Antibody Industry in China Sees Major Opportunities
GEN Exclusives
2019-05-10
China's global investment push opens doors for domestic biotechs
BIOPHARMA DIVE
